[{"id":"8009476b-712f-4b6f-9467-7f222bfb4fb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05450562","created_at":"2022-07-08T14:55:40.019Z","updated_at":"2024-07-02T16:35:00.176Z","phase":"Phase 1/2","brief_title":"Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05450562","lead_sponsor":"Sanofi","biomarkers":" ALK • GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["ALK • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Libtayo (cemiplimab-rwlc) • SAR444200"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 09/20/2022","start_date":" 09/20/2022","primary_txt":" Primary completion: 12/12/2030","primary_completion_date":" 12/12/2030","study_txt":" Completion: 12/12/2030","study_completion_date":" 12/12/2030","last_update_posted":"2024-05-30"}]